Enhancer profiling from plasma allowed us to infer activity of therapeutically targetable TFs from plasma, including estrogen receptor (ER) in breast cancer plasma, androgen receptor (AR) in prostate cancer and HIF2α in renal cell carcinoma (RCC) (Extended Data Fig. 8). This evidence concerns the gene AR and prostate carcinoma.